<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486614</url>
  </required_header>
  <id_info>
    <org_study_id>RJ114/N168</org_study_id>
    <nct_id>NCT02486614</nct_id>
  </id_info>
  <brief_title>Effect of Citrate on the Coagulation System in Patients Receiving CRRT</brief_title>
  <acronym>Citroco</acronym>
  <official_title>The Effect of Regional Citrate Anti-coagulation on the Coagulation System in Critically Ill Patients Receiving Continuous Renal Replacement Therapy for Acute Kidney Injury - an Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of regional citrate anti-coagulation on&#xD;
      different pathways of the coagulation system in critically ill patients with acute kidney&#xD;
      injury. This will form the basis for future studies where the investigators plan to focus on&#xD;
      patients with premature circuit clotting despite optimal post-filtrate ionised calcium&#xD;
      parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of clinical trial:&#xD;
&#xD;
      To evaluate the effect of regional citrate anti-coagulation on different pathways of the&#xD;
      coagulation system in critically ill patients with acute kidney injury.&#xD;
&#xD;
      Patient population:&#xD;
&#xD;
      critically ill patients with acute kidney injury requiring citrate-based continuous renal&#xD;
      replacement therapy (CRRT)&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      Changes from baseline in a number of measures of coagulability (platelet count; Prothrombin&#xD;
      Time; Activated Partial Thromboplastin Time ratio; fibrinogen; d-dimers; Thrombin generation&#xD;
      assay; Clot lysis; platelet function analysis 100) in both the blood within the patient's&#xD;
      systemic circulation and the CRRT circuit over the course of 72 hours of regional&#xD;
      anticoagulation with citrate.&#xD;
&#xD;
      Number of Subjects/Patients:&#xD;
&#xD;
      12 patients with complete data.&#xD;
&#xD;
      Trial Design:&#xD;
&#xD;
      Prospective non-interventional study.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Change from baseline in a number of measures of coagulability.&#xD;
&#xD;
      Main Inclusion Criteria:&#xD;
&#xD;
      Adult intensive care patients undergoing CRRT with citrate regional anti-coagulation for AKI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of parameters of coagulability during Continuous Renal Replacement Therapy (CRRT) with citrate anticoagulation</measure>
    <time_frame>72 hours</time_frame>
    <description>Changes of coagulation parameters (Full Blood Count, prothrombin time, activated partial thromboplastin time ratio, fibrinogen, d-dimer, thrombin generation, clot lysis and platelet function analysis) during citrate-based CRRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of baseline coagulation status before initiation of citrate-based CRRT</measure>
    <time_frame>Before initiation of CRRT</time_frame>
    <description>Determination of parameters of coagulation [Full Blood Count (FBC), prothrombin time (PT), activated partial thromboplastin time ratio (APTTr), fibrinogen, D-dimers, antithrombin activity, protein C activity, free Protein S antigen, resistance to activated protein C screening, homocysteine, prothrombin 20210 mutation test, factor VIII level, Von Willebrand factor antigen, Dilute Russell's Viper Venom Time, dilute activated partial thromboplastin time, anticardiolipin antibodies, anti-beta 2 glycoprotein I antibodies, thrombin generation assay, clot lysis, platelet function 1+2, Thrombin-Antithrombin and platelet function analysis] before initiation of citrate-based CRRT</description>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Acute Kidney Failure</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRRT</intervention_name>
    <description>citrate based continuous renal replacement therapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adults with acute kidney injury requiring citrate based continuous renal replacement&#xD;
        therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  acute kidney injury treated with citrate based continuous renal replacement therapy&#xD;
             (CRRT)&#xD;
&#xD;
          -  age &gt;18 years.&#xD;
&#xD;
          -  expected to require &gt;72 hours of CRRT.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known preexisting clotting tendency&#xD;
&#xD;
          -  Known preexisting bleeding tendency&#xD;
&#xD;
          -  Disseminated Intravascular Coagulation (DIC)&#xD;
&#xD;
          -  Prior transfusion of any blood product in the 24 hours before enrolment&#xD;
&#xD;
          -  Active bleeding (ie. needing blood transfusion) at time of enrolment&#xD;
&#xD;
          -  Haemoglobin at time of enrolment &lt;75g/L&#xD;
&#xD;
          -  Haematocrit at time of enrolment &gt;0.55&#xD;
&#xD;
          -  Patient would refuse Red Blood Cell transfusion (for example Jehova's Witness).&#xD;
&#xD;
          -  Platelet count at time of enrolment &lt;100x103/ÂµL&#xD;
&#xD;
          -  Treatment with any anticoagulant or antiplatelet agent at time of enrolment or within&#xD;
             7 days of enrolment with the exception of heparin or low molecular weight heparin for&#xD;
             DVT prophylaxis.&#xD;
&#xD;
          -  Intravenous heparin exposure within 4 hours of commencing citrate anticoagulation.&#xD;
&#xD;
          -  Malnourished: BMI &lt;18.5kg/m2 or unplanned weight loss &gt;10% actual body weight (ABW) in&#xD;
             preceding 6 months or BMI &lt;20kg/m2 and unplanned weight loss &gt;5% ABW in preceding 6&#xD;
             months.&#xD;
&#xD;
          -  CRRT prescribed for an indication other than AKI (for example poisoning).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlies Ostermann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's &amp; St Thomas' Foundation Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

